TechMARK movers: Alizyme chief exec steps down

6th Jul 2009 14:21

Alizyme has lost chief executive Tim McCarthy as part of the drug developer's reconstruction effort.Non-executive director Alan Goodman will take charge of the day to day affairs of the business after McCarthy stepped down with immediate effect.The US Food and Drug Administration (FDA) has cleared the way for gene therapy company Oxford Biomedica to develop its cancer vaccine TroVax.America's health regulator completed its review of the Phase III TRIST study of TroVax and "acknowledged all of the points raised" by the British company.FTSE TechMARK - RisersPuricore (PURI) 16.00p +10.34%Morse (MOR) 19.75p +8.22%Xaar (XAR) 102.00p +5.70%Filtronic (FTC) 37.75p +4.14%Intec Telecom (ITL) 77.75p +4.01%RM Group (RM.) 165.00p +2.96%E2V Technologies (E2V) 67.25p +2.67%Skyepharma (SKP) 120.00p +2.13%Alizyme (AZM) 3.00p +2.04%Antisoma (ASM) 26.00p +1.96%FTSE TechMARK - FallersRenovo Group (RNVO) 24.75p -5.71%Parity Group (PTY) 12.50p -3.85%Anite Group (AIE) 28.50p -3.39%Biocompatibles International (BII) 178.00p -3.26%Sinclair Pharma (SPH) 25.00p -2.91%KCOM Group (KCOM) 26.25p -2.78%Elan Corporation (ELA) € 5.68 -2.74%XP Power (XPP) 203.50p -2.40%Triad Group (TRD) 42.00p -2.33%Innovation Group (TIG) 9.50p -1.86%